Mark E. Hensley
Executive VP & COOMr. Mark E. Hensley serves as Executive Vice President and Chief Operating Officer of Heron Therapeutics, Inc. since April 2025. He is Chairman of Calliditas Therapeutics AB (publ) from September 30, 2024. He served as Chief Executive Officer since October 2021 and had been Chief Commercial Officer at Veloxis Pharmaceuticals A/S since January 03, 2019 until October 2021. Mr. Hensley has been Chief Executive Officer since 2022 and served as Chief Commercial Officer of Veloxis Pharmaceuticals, Inc. since December 2018 until 2022. Mr. Hensley joined Veloxis in April 2016 as National Sales Director. Mr. Hensley has served as the vice-president of sales for Veloxis Pharmaceuticals Inc. since May 2017 where he has been responsible for all sales and marketing related functions. Prior to joining Veloxis, Mr. Hensley served in various senior leadership roles of increasing responsibility for Chiesi USA, Inc. and Cornerstone Therapeutics Inc. He holds a BS in Biology, with a minor in Chemistry, from the University of North Texas.
Positions
- Company NameHeron Therapeutics, Inc.Stock CodeHRTXPositionExecutive VP & COOColleagues
- CACraig Alexander CollardCEO & Director
- AMAdam MorganIndependent Chairman
- IDIra DuarteExecutive VP & CFO
- WPWilliam P. ForbesExecutive VP & Chief Development Officer
- MJMelissa JarelVice President of Legal
- CACraig A. JohnsonLead Independent Director
- CWChristian WaageIndependent Director
- SDSharmila DissanaikeIndependent Director
